Reports Q3 revenue $1.7M, consensus $1.75M. “The recent progress we have made across our portfolio of internal and partnered programs illustrates our commitment to delivering results,” said Sean McClain, Founder and CEO. “Through achieving a milestone in our collaboration with AstraZeneca, adding a new partnership with Twist, and continuing to advance each of our own proprietary internal programs, the last few months represent another period of solid execution for Absci (ABSI).”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- ABSI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cathie Wood’s ARK Investment bought 94.4K shares of Absci today
- Cathie Wood’s ARK Investment bought 232K shares of Absci today
- Absci, Twist Bioscience collaborate to design antibody using generative AI
- Cathie Wood’s ARK Investment bought 401K shares of Absci today